Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Preparation of Thermosensitive Gel for Controlled Release of Levofloxacin and Their Application in the Treatment of Multidrug-Resistant Bacteria

Texto completo
Autor(es):
Alves, Danilo Antonini ; Machado, Daisy ; Melo, Adriana ; Carneiro Pereira, Rafaella Fabiana ; Severino, Patricia ; de Hollanda, Luciana Maria ; Araujo, Daniele Ribeiro ; Lancellotti, Marcelo
Número total de Autores: 8
Tipo de documento: Artigo Científico
Fonte: BIOMED RESEARCH INTERNATIONAL; 2016.
Citações Web of Science: 2
Resumo

Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration. Chemically, levofloxacin is the levorotatory isomer (L-isomer) of racemate ofloxacin, a fluoroquinolone antibacterial agent. Quinolone derivatives rapidly and specifically inhibit the synthesis of bacterial DNA. Levofloxacin has in vitro activity against a broad range of aerobic and anaerobic Gram-positive and Gram-negative bacteria. However, formulation of combined poloxamers thermoregulated (as Pluronic (R) F127) and levofloxacin for use in multiresistant bacterial treatment were poorly described in the current literature. Thus, the aim of the present work is to characterize poloxamers for levofloxacin controlled release and their use in the treatment of multidrug bacterial resistance. Micelles were produced in colloidal dispersions, with a diameter between 5 and 100 nm, which form spontaneously from amphiphilic molecules under certain conditions as concentration and temperature. Encapsulation of levofloxacin into nanospheres showed efficiency and enhancement of antimicrobial activity against Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae when compared with only levofloxacin. Furthermore, all formulations were not cytotoxic for NIH/3T3 cell lineage. In conclusion, poloxamers combined with levofloxacin have shown promising results, better than alone, decreasing the minimal inhibitory concentration of the studied bacterial multiresistance strains. In the future, this new formulation will be used after being tested in animal models in patients with resistant bacterial strains. (AU)

Processo FAPESP: 11/21822-3 - Mecanismos de aquisição de resistência a antibióticos por bactérias causadoras de infecção do trato urinário - uma abordagem farmacogenômica e biofarmacêutica
Beneficiário:Danilo Antonini Alves
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 11/21685-6 - Mecanismos de aquisição de resistência a antibióticos por bactérias causadoras de infecção do trato urinário: uma abordagem farmacogenômica e biofarmacêutica
Beneficiário:Marcelo Lancellotti
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 14/14457-5 - Carreadores baseados em lipídios (SLN/NLC e lipossomas com gradiente iônico) como estratégia para aumentar a encapsulação e a potência de anestésicos locais
Beneficiário:Eneida de Paula
Linha de fomento: Auxílio à Pesquisa - Temático